{"id":"levodopa-carbidopa","safety":{"commonSideEffects":[{"rate":null,"effect":"Dyskinesia"},{"rate":null,"effect":"Motor fluctuations"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Orthostatic hypotension"},{"rate":null,"effect":"Hallucinations"},{"rate":null,"effect":"Confusion"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":{"setId":"095a08b6-b0b8-4f88-b759-67e8b87287a0","title":"CREXONT (CARBIDOPA AND LEVODOPA) CAPSULE, EXTENDED RELEASE [AMNEAL PHARMACEUTICALS LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levodopa is a precursor to dopamine that crosses the blood-brain barrier, where it is converted to dopamine by aromatic amino acid decarboxylase (AADC). Carbidopa is a decarboxylase inhibitor that does not cross the blood-brain barrier, so it blocks peripheral conversion of levodopa to dopamine, reducing side effects and increasing the amount of levodopa available for central nervous system conversion. This combination restores dopamine levels in Parkinson's disease patients.","oneSentence":"Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while carbidopa inhibits premature conversion of levodopa in the periphery, allowing more to reach the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:58.774Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"},{"name":"Parkinsonism secondary to carbon monoxide poisoning or manganese intoxication"}]},"trialDetails":[{"nctId":"NCT05909267","phase":"NA","title":"Dopamine Modulation of Motivation and Motor Function in Major Depression & Inflammation","status":"RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2023-07-26","conditions":"Depressive Disorder, Major","enrollment":165},{"nctId":"NCT05781711","phase":"PHASE2","title":"Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-01-06","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT06113640","phase":"PHASE2, PHASE3","title":"Montelukast in Parkinson Disease","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2023-11-05","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT07151378","phase":"PHASE3","title":"Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2025-10-27","conditions":"PARKINSON DISEASE (Disorder)","enrollment":150},{"nctId":"NCT07444892","phase":"PHASE2","title":"Levodopa for Diabetic Retinopathy","status":"COMPLETED","sponsor":"Emory University","startDate":"2022-04-18","conditions":"Diabetic Retinopathy","enrollment":230},{"nctId":"NCT07442591","phase":"PHASE1","title":"A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants","status":"NOT_YET_RECRUITING","sponsor":"Shanghai WD Pharmaceutical Co., Ltd.","startDate":"2026-03","conditions":"Healhty","enrollment":12},{"nctId":"NCT04469959","phase":"PHASE2","title":"Dopaminergic Dysfunction in Late-Life Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-02-15","conditions":"Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant","enrollment":100},{"nctId":"NCT06831500","phase":"PHASE1, PHASE2","title":"Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease.","status":"RECRUITING","sponsor":"Julien Bally","startDate":"2025-07-18","conditions":"Multi-system Atrophy - Parkinsonian Type, Orthostatic Hypotension, Dysautonomic, Parkinson Disease","enrollment":36},{"nctId":"NCT06075771","phase":"PHASE4","title":"Dopaminergic Therapy for Anhedonia - 2","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-11-21","conditions":"Anhedonia, Depression","enrollment":70},{"nctId":"NCT07370532","phase":"PHASE2","title":"Etoricoxib in Patients With Parkinsonian Disease","status":"NOT_YET_RECRUITING","sponsor":"Ihab Elsayed Hassan","startDate":"2026-06-30","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT07313176","phase":"","title":"Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease","status":"RECRUITING","sponsor":"Britannia Pharmaceuticals Ltd.","startDate":"2026-01","conditions":"Advanced Parkinson Disease","enrollment":215},{"nctId":"NCT05043103","phase":"","title":"Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Britannia Pharmaceuticals Ltd.","startDate":"2021-07-06","conditions":"Advanced Parkinson Disease","enrollment":312},{"nctId":"NCT06785298","phase":"PHASE2, PHASE3","title":"Fexofenadine as Adjuvant Therapy in Parkinson Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2024-12-10","conditions":"Parkinson Disease","enrollment":46},{"nctId":"NCT06587217","phase":"PHASE1, PHASE2","title":"Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2024-10-29","conditions":"Parkinsonian Signs in Older Persons","enrollment":5},{"nctId":"NCT07229664","phase":"PHASE2, PHASE3","title":"Vinpocetine in Patients With Parkinsonian Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-11-10","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT05708274","phase":"PHASE1","title":"Pharmacological Agents for Chronic Spinal Cord Injury (SCI)","status":"COMPLETED","sponsor":"Bronx VA Medical Center","startDate":"2023-01-20","conditions":"Spinal Cord Injuries","enrollment":25},{"nctId":"NCT07246278","phase":"PHASE1, PHASE2","title":"Celecoxib in Parkinson Disease as Adjuvant Therapy","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-11-20","conditions":"Parkinson Disease","enrollment":80},{"nctId":"NCT07229651","phase":"PHASE2, PHASE3","title":"Metformin in Parkinson Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-11-10","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT03022318","phase":"PHASE2","title":"Carbidopa-levodopa in Neovascular AMD","status":"COMPLETED","sponsor":"Snyder, Robert W., M.D., Ph.D., P.C.","startDate":"2017-05-02","conditions":"Age-related Macular Degeneration","enrollment":20},{"nctId":"NCT03023059","phase":"PHASE2","title":"Dose Ranging Study of Carbidopa-levodopa","status":"COMPLETED","sponsor":"Snyder, Robert W., M.D., Ph.D., P.C.","startDate":"2017-05-02","conditions":"Age-related Macular Degeneration","enrollment":35},{"nctId":"NCT03197493","phase":"PHASE2","title":"Extension, Carbidopa-levodopa in Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Snyder, Robert W., M.D., Ph.D., P.C.","startDate":"2017-08-01","conditions":"Macula; Degeneration, Retina","enrollment":35},{"nctId":"NCT07001150","phase":"PHASE2","title":"Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-05-10","conditions":"Parkinson Disease","enrollment":50},{"nctId":"NCT06765668","phase":"PHASE4","title":"A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease","status":"RECRUITING","sponsor":"Impax Laboratories, LLC","startDate":"2025-02-12","conditions":"Parkinson Disease","enrollment":220},{"nctId":"NCT04750226","phase":"PHASE3","title":"Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2021-02-18","conditions":"Parkinson's Disease (PD)","enrollment":118},{"nctId":"NCT05962957","phase":"PHASE2","title":"Role of Pentoxifylline and Celecoxib in Parkinsonism","status":"COMPLETED","sponsor":"Mostafa Bahaa","startDate":"2023-08-07","conditions":"Parkinson Disease","enrollment":80},{"nctId":"NCT04379050","phase":"PHASE3","title":"Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-06-08","conditions":"Parkinson's Disease (PD)","enrollment":130},{"nctId":"NCT04821830","phase":"PHASE4","title":"Vigor and the LDR in Parkinson Disease","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2020-02-12","conditions":"Parkinson Disease","enrollment":19},{"nctId":"NCT05471609","phase":"EARLY_PHASE1","title":"Sustained Release Oral Formulation for Treatment of Parkinson's Disease","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2025-06-12","conditions":"Healthy Volunteers","enrollment":6},{"nctId":"NCT02339064","phase":"PHASE3","title":"Infusion of Apomorphine: Long-term Safety Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","startDate":"2015-02","conditions":"Idiopathic Parkinson's Disease","enrollment":99},{"nctId":"NCT06219915","phase":"PHASE1, PHASE2","title":"Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2024-03-15","conditions":"Parkinsonian Signs in Older Persons","enrollment":13},{"nctId":"NCT02994719","phase":"","title":"Gait Analysis in Neurological Disease","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2016-03-01","conditions":"Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease","enrollment":120},{"nctId":"NCT02726386","phase":"PHASE2","title":"A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"NeuroDerm Ltd.","startDate":"2016-05-04","conditions":"Parkinson's Disease","enrollment":214},{"nctId":"NCT04006210","phase":"PHASE3","title":"Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations","status":"ACTIVE_NOT_RECRUITING","sponsor":"NeuroDerm Ltd.","startDate":"2019-09-30","conditions":"Parkinson's Disease","enrollment":381},{"nctId":"NCT06976346","phase":"PHASE1","title":"Relative Bioavailability Study of HRG2010 in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-09-10","conditions":"Parkinson's Disease","enrollment":16},{"nctId":"NCT06013956","phase":"PHASE4","title":"Personalized Real-Time DBS and PD Mechanisms","status":"RECRUITING","sponsor":"David Escobar","startDate":"2023-08-29","conditions":"Parkinson Disease","enrollment":25},{"nctId":"NCT05132660","phase":"EARLY_PHASE1","title":"Treating Early Stage Diabetic Retinopathy","status":"ENROLLING_BY_INVITATION","sponsor":"VA Office of Research and Development","startDate":"2022-07-01","conditions":"Diabetic Retinopathy","enrollment":244},{"nctId":"NCT06596876","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-11-06","conditions":"Parkinson's Disease","enrollment":450},{"nctId":"NCT05369533","phase":"PHASE1, PHASE2","title":"Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2022-08-01","conditions":"Stroke","enrollment":25},{"nctId":"NCT05885360","phase":"PHASE4","title":"Istradefylline Effect Protocol on Parkinson's Disease Tremor","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2023-01-20","conditions":"Parkinson Disease, Tremor","enrollment":27},{"nctId":"NCT04990284","phase":"PHASE4","title":"eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2021-11-29","conditions":"Parkinson Disease","enrollment":106},{"nctId":"NCT06432309","phase":"NA","title":"Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease","status":"COMPLETED","sponsor":"University Hospital of Ferrara","startDate":"2022-07-01","conditions":"Parkinson Disease, Effect of Drug","enrollment":22},{"nctId":"NCT04735627","phase":"NA","title":"Real-Time Levodopa Level Monitoring in Parkinson Disease","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2021-12-07","conditions":"Parkinson Disease","enrollment":20},{"nctId":"NCT06003608","phase":"","title":"Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nimble Science Ltd.","startDate":"2024-02-19","conditions":"Parkinson Disease","enrollment":100},{"nctId":"NCT05285683","phase":"PHASE2","title":"The Role of Brain Dopamine in Chronic Pain","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2024-01-31","conditions":"Chronic Pain","enrollment":10},{"nctId":"NCT04723147","phase":"PHASE4","title":"DTA (Dopaminergic Therapy for Anhedonia) Study","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-01-29","conditions":"Depression, Anhedonia","enrollment":19},{"nctId":"NCT05463367","phase":"PHASE2","title":"Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2021-01-01","conditions":"Opioid Use, Opioid Dependence, Opioid-use Disorder","enrollment":60},{"nctId":"NCT03374917","phase":"PHASE1","title":"A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-04-18","conditions":"Parkinson's Disease (PD)","enrollment":20},{"nctId":"NCT03735901","phase":"PHASE3","title":"Enhancement of Stroke Rehabilitation With Levodopa","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2019-06-14","conditions":"Acute Stroke, Stroke Rehabilitation","enrollment":610},{"nctId":"NCT06626152","phase":"PHASE2","title":"Measuring Psychomotor Response to L-DOPA Challenge As a Biomarker for Outcomes in Late-Life Depression: a Pilot Feasibility Trial","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2024-08-15","conditions":"Major Depressive Disorder","enrollment":50},{"nctId":"NCT06614153","phase":"PHASE2","title":"Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuations","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-05-16","conditions":"Parkinson's Disease","enrollment":61},{"nctId":"NCT01725802","phase":"PHASE1","title":"A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2012-12-16","conditions":"Parkinson's Disease","enrollment":8},{"nctId":"NCT02096601","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2014-08-11","conditions":"Parkinson's Disease","enrollment":16},{"nctId":"NCT00456794","phase":"PHASE2","title":"12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2002-03","conditions":"Parkinson's Disease","enrollment":325},{"nctId":"NCT00199420","phase":"PHASE3","title":"A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2004-07","conditions":"Parkinson's Disease","enrollment":580},{"nctId":"NCT00955045","phase":"PHASE2, PHASE3","title":"A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2002-08","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT00456586","phase":"PHASE2","title":"12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2002-04","conditions":"Parkinson's Disease","enrollment":180},{"nctId":"NCT03451500","phase":"PHASE2","title":"Carbidopa-Levodopa in Dry AMD With Geographic Atrophy","status":"TERMINATED","sponsor":"Snyder, Robert W., M.D., Ph.D., P.C.","startDate":"2018-07-01","conditions":"Age Related Macular Degeneration","enrollment":7},{"nctId":"NCT00199407","phase":"PHASE3","title":"A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2004-06","conditions":"Parkinson's Disease","enrollment":230},{"nctId":"NCT02763137","phase":"PHASE2","title":"Intermittent Oral Administration vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Fluctuating Parkinsonian Patients","status":"COMPLETED","sponsor":"IRCCS San Raffaele Roma","startDate":"2014-07-30","conditions":"Parkinson Disease","enrollment":18},{"nctId":"NCT04325503","phase":"PHASE1, PHASE2","title":"Neurobiological Drivers of Mobility Resilience: The Dopaminergic System","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2021-02-08","conditions":"Parkinsonian Signs in Older Persons","enrollment":14},{"nctId":"NCT05087914","phase":"PHASE2","title":"Novel Non-opioid Post-surgical Pain Treatment in Females","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2021-11-01","conditions":"Acute Pain, Bunionectomy, Toe Fusion","enrollment":""},{"nctId":"NCT03111485","phase":"PHASE4","title":"Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2017-05-24","conditions":"Parkinson's Disease, Obstructive Sleep Apnea","enrollment":36},{"nctId":"NCT02480803","phase":"PHASE4","title":"INfusion VErsus STimulation in Parkinson's Disease","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2014-12-19","conditions":"Parkinson's Disease","enrollment":51},{"nctId":"NCT06236230","phase":"PHASE4","title":"Basic and Clinical Studies of Levodopa/Carbidopa/Entacapone in the Treatment of Early Parkinson's Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2023-11-15","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT02604914","phase":"PHASE1","title":"A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2015-05-29","conditions":"Parkinson's Disease","enrollment":36},{"nctId":"NCT01486628","phase":"PHASE1","title":"Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2012-04-30","conditions":"Parkinson's Disease","enrollment":36},{"nctId":"NCT01883505","phase":"PHASE2","title":"A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2014-01-06","conditions":"Parkinson's Disease","enrollment":30},{"nctId":"NCT06180720","phase":"PHASE1","title":"Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in the Postprandial State in Healthy Chinese Subjects","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2023-12-20","conditions":"Healthy","enrollment":36},{"nctId":"NCT00439049","phase":"","title":"Substance Abuse Pre-Treatment Screening Study","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2005-10","conditions":"Cocaine Abuse, Cocaine Dependence, Opiate Dependence","enrollment":7500},{"nctId":"NCT03000569","phase":"PHASE2","title":"A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease","status":"COMPLETED","sponsor":"Biogen","startDate":"2016-11-30","conditions":"Parkinson Disease","enrollment":29},{"nctId":"NCT06115538","phase":"PHASE4","title":"Comparison of Dopamin Level in Idiopathic Parkinson's Patients","status":"UNKNOWN","sponsor":"Ankara Ataturk Sanatorium Training and Research Hospital","startDate":"2023-10-01","conditions":"Parkinson Disease, Treatment Adherence","enrollment":96},{"nctId":"NCT02549092","phase":"PHASE3","title":"A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-26","conditions":"Advanced Parkinson's Disease","enrollment":89},{"nctId":"NCT03781167","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-04-29","conditions":"Parkinson's Disease (PD)","enrollment":244},{"nctId":"NCT04052776","phase":"PHASE1","title":"Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2020-09-11","conditions":"Spinal Cord Injuries, Drug Effect","enrollment":3},{"nctId":"NCT02549573","phase":"PHASE4","title":"Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®","status":"TERMINATED","sponsor":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","startDate":"2016-01","conditions":"Parkinson's Disease, Motor Symptoms","enrollment":13},{"nctId":"NCT04558112","phase":"PHASE2","title":"Improving Therapeutic Learning for PTSD","status":"UNKNOWN","sponsor":"University of Wisconsin, Madison","startDate":"2021-02-18","conditions":"PTSD, Post Traumatic Stress Disorder","enrollment":120},{"nctId":"NCT01770145","phase":"PHASE4","title":"Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)","status":"COMPLETED","sponsor":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","startDate":"2012-12","conditions":"Parkinson's Disease, Motor Symptoms, Akinesia","enrollment":127},{"nctId":"NCT05976737","phase":"PHASE1","title":"Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in Healthy Chinese Subjects","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2023-08-17","conditions":"Healthy","enrollment":68},{"nctId":"NCT03243552","phase":"PHASE2","title":"Proof of Mechanism Study for the Treatment of Social Anhedonia in ASD","status":"UNKNOWN","sponsor":"University of California, Los Angeles","startDate":"2017-06-01","conditions":"ASD","enrollment":56},{"nctId":"NCT03944785","phase":"","title":"Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2017-11-30","conditions":"Idiopathic Parkinson Disease","enrollment":164},{"nctId":"NCT02577523","phase":"PHASE2","title":"A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2015-12-29","conditions":"Parkinson's Disease","enrollment":38},{"nctId":"NCT03761030","phase":"PHASE4","title":"L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2019-01-09","conditions":"Major Depressive Disorder, Dysthymia, Depression","enrollment":51},{"nctId":"NCT04493320","phase":"PHASE4","title":"1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2021-02-10","conditions":"Depression, Cognitive Impairment, Gait Impairment","enrollment":5},{"nctId":"NCT05094050","phase":"PHASE1","title":"Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-01-18","conditions":"Parkinson's Disease","enrollment":16},{"nctId":"NCT00590122","phase":"PHASE4","title":"Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2006-10","conditions":"Parkinson's Disease","enrollment":20},{"nctId":"NCT04952194","phase":"PHASE4","title":"Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-01-01","conditions":"Parkinson Disease","enrollment":180},{"nctId":"NCT04742348","phase":"PHASE4","title":"Research on Translational Outcomes of Alcohol (Project RETRO)","status":"WITHDRAWN","sponsor":"University of Washington","startDate":"2023-02","conditions":"Alcohol Drinking","enrollment":""},{"nctId":"NCT03670953","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2018-11-06","conditions":"Parkinson's Disease (Disorder)","enrollment":630},{"nctId":"NCT05083260","phase":"PHASE1, PHASE2","title":"NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa","status":"COMPLETED","sponsor":"BioVie Inc.","startDate":"2022-01-04","conditions":"Parkinson Disease","enrollment":46},{"nctId":"NCT04650217","phase":"PHASE4","title":"Levodopa and Exercise for Older Adults With Depression and Psychomotor Slowing","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2021-10-07","conditions":"Depressive Disorder","enrollment":1},{"nctId":"NCT04500106","phase":"","title":"Study to Assess Participant/Caregiver/Investigator Satisfaction of Video-Assisted Telenursing in Adult Participants With Parkinson's Disease Treated With Levodopa-Carbidopa Intestinal Gel","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-04-22","conditions":"Parkinson's Disease","enrollment":41},{"nctId":"NCT00660673","phase":"PHASE3","title":"Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2009-11-13","conditions":"Advanced Parkinson's Disease","enrollment":262},{"nctId":"NCT04787965","phase":"","title":"Opicapone Treatment Initiation Open-Label Study","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2021-03-01","conditions":"Parkinson Disease","enrollment":239},{"nctId":"NCT04380142","phase":"PHASE3","title":"Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-10-19","conditions":"Parkinson's Disease (PD)","enrollment":174},{"nctId":"NCT04000919","phase":"PHASE2, PHASE3","title":"Effects of 5HTP and LDOPA on CNS Excitability After SCI","status":"SUSPENDED","sponsor":"Jessica M D'Amico","startDate":"2019-06-19","conditions":"Spinal Cord Injuries","enrollment":30},{"nctId":"NCT03205956","phase":"PHASE1","title":"Measuring Parkinson's Disease Progression","status":"COMPLETED","sponsor":"Kevin J. Black, MD","startDate":"2017-10-19","conditions":"Parkinson's Disease","enrollment":31},{"nctId":"NCT04244058","phase":"EARLY_PHASE1","title":"Changes in Glutamatergic Neurotransmission of Severe TBI Patients","status":"SUSPENDED","sponsor":"Weill Medical College of Cornell University","startDate":"2020-09-23","conditions":"Disorder of Consciousness, Traumatic Brain Injury","enrollment":30},{"nctId":"NCT02513485","phase":"PHASE4","title":"Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-10-09","conditions":"Depression","enrollment":57},{"nctId":"NCT04778176","phase":"PHASE2","title":"Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa Via the DopaFuse® Delivery System in Parkinson's Disease Patients","status":"COMPLETED","sponsor":"SynAgile Corporation","startDate":"2021-06-16","conditions":"Parkinson's Disease","enrollment":17},{"nctId":"NCT03929068","phase":"PHASE1","title":"Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-05-13","conditions":"Amyotrophic Lateral Sclerosis, Motor Neuron Disease","enrollment":15}],"_emaApprovals":[],"_faersSignals":[{"count":241,"reaction":"DYSKINESIA"},{"count":220,"reaction":"FALL"},{"count":154,"reaction":"DRUG INEFFECTIVE"},{"count":153,"reaction":"HALLUCINATION"},{"count":149,"reaction":"PARKINSON^S DISEASE"},{"count":141,"reaction":"GAIT DISTURBANCE"},{"count":131,"reaction":"ON AND OFF PHENOMENON"},{"count":129,"reaction":"FATIGUE"},{"count":127,"reaction":"TREMOR"},{"count":118,"reaction":"DIZZINESS"}],"_approvalHistory":[],"publicationCount":1305,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sinemet"],"phase":"marketed","status":"active","brandName":"Levodopa / Carbidopa","genericName":"Levodopa / Carbidopa","companyName":"Ross D. Zafonte, MD","companyId":"ross-d-zafonte-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while carbidopa inhibits premature conversion of levodopa in the periphery, allowing more to reach the brain. Used for Parkinson's disease, Parkinsonism secondary to carbon monoxide poisoning or manganese intoxication.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}